D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
180 Life Sciences Corp. (NASDAQ:ATNF), a micro-cap biotech company currently valued at $5 million and trading near $0.88 per share, announced Wednesday that its 2025 Annual Meeting of Shareholders is scheduled for July 24, 2025. The stock has faced significant challenges, declining nearly 70% over the past six months according to InvestingPro data. The company stated in a press release filed with the Securities and Exchange Commission that it reserves the right to change the meeting date prior to that time. Details regarding the time and location will be provided in the definitive proxy statement to be filed with the SEC. While the company maintains a favorable cash-to-debt position, InvestingPro analysis indicates the company faces profitability challenges, with additional insights available to subscribers.
Shareholders of record as of the close of business on June 30, 2025, will be entitled to receive notice of and vote at the annual meeting. The company also noted that it may change the record date before the meeting.
Shareholder proposals intended for inclusion in the company’s proxy materials must be delivered or mailed to 180 Life Sciences’ principal executive offices and received by the close of business on July 7, 2025. This deadline also applies to director nominations and other business proposals to be presented at the meeting, whether submitted under SEC Rule 14a-8 or otherwise. All proposals must comply with applicable SEC rules, Delaware law, and the company’s bylaws to be considered timely and properly brought before the meeting.
The information in this article is based on a press release statement included in the company’s Form 8-K filing with the SEC.
In other recent news, 180 Life Sciences Corp. announced significant developments in both its biotechnology and corporate strategies. The company has received a Notice of Allowance from the United States Patent and Trademark Office for a method aimed at mitigating Post-Operative Cognitive Dysfunction (POCD) through the use of an anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibody. This potential patent could offer protection for a therapeutic approach addressing a significant medical need, although the formal issuance of the patent is still pending. Additionally, 180 Life Sciences has entered into an agreement to repurchase and cancel approximately 23.1% of its outstanding shares, a move designed to reduce shareholder dilution and streamline its capital structure. This agreement involves a $1 million payment to Elray Resources, Inc. and Luxor Capital, LLC, to be completed by April 2026. CEO Blair Jordan emphasized that these actions align with the company’s strategic pivot towards the iGaming sector, focusing on the development and acquisition of online casino businesses. The share repurchase agreement also includes a voting alignment with the company’s Board of Directors by Elray Resources. These steps are part of 180 Life Sciences’ broader efforts to enhance stockholder value and leverage its proprietary Technology Gaming Platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.